nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—CYP2C8—Levothyroxine—hypothyroidism	0.101	0.227	CbGbCtD
Ponatinib—CYP2C8—Liotrix—hypothyroidism	0.0987	0.222	CbGbCtD
Ponatinib—ABCB1—Liothyronine—hypothyroidism	0.0685	0.154	CbGbCtD
Ponatinib—ABCB1—Levothyroxine—hypothyroidism	0.0685	0.154	CbGbCtD
Ponatinib—ABCB1—Liotrix—hypothyroidism	0.0668	0.15	CbGbCtD
Ponatinib—CYP3A4—Levothyroxine—hypothyroidism	0.041	0.0923	CbGbCtD
Ponatinib—FGFR3—epiphyseal plate—hypothyroidism	0.0312	0.128	CbGeAlD
Ponatinib—KIT—seminiferous tubule of testis—hypothyroidism	0.0117	0.0481	CbGeAlD
Ponatinib—RET—parathyroid gland—hypothyroidism	0.00878	0.036	CbGeAlD
Ponatinib—Cardiac failure congestive—Liothyronine—hypothyroidism	0.00611	0.0357	CcSEcCtD
Ponatinib—Venous thrombosis—Liotrix—hypothyroidism	0.00511	0.0298	CcSEcCtD
Ponatinib—Angina pectoris—Liothyronine—hypothyroidism	0.00467	0.0272	CcSEcCtD
Ponatinib—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00421	0.0246	CcSEcCtD
Ponatinib—Myocardial infarction—Liothyronine—hypothyroidism	0.00419	0.0244	CcSEcCtD
Ponatinib—FGFR4—heart—hypothyroidism	0.00374	0.0153	CbGeAlD
Ponatinib—Arrhythmia—Liothyronine—hypothyroidism	0.00342	0.02	CcSEcCtD
Ponatinib—FGFR4—pituitary gland—hypothyroidism	0.00313	0.0128	CbGeAlD
Ponatinib—Cellulitis—Liotrix—hypothyroidism	0.00303	0.0177	CcSEcCtD
Ponatinib—Hypocalcaemia—Liotrix—hypothyroidism	0.00301	0.0176	CcSEcCtD
Ponatinib—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.003	0.0175	CcSEcCtD
Ponatinib—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.003	0.0175	CcSEcCtD
Ponatinib—Creatinine increased—Liotrix—hypothyroidism	0.0029	0.0169	CcSEcCtD
Ponatinib—Hypertension—Liothyronine—hypothyroidism	0.00288	0.0168	CcSEcCtD
Ponatinib—FGFR4—adrenal gland—hypothyroidism	0.00279	0.0114	CbGeAlD
Ponatinib—FGFR4—blood—hypothyroidism	0.00279	0.0114	CbGeAlD
Ponatinib—Cardiac failure—Levothyroxine—hypothyroidism	0.00279	0.0163	CcSEcCtD
Ponatinib—Cardiac failure—Dextrothyroxine—hypothyroidism	0.00279	0.0163	CcSEcCtD
Ponatinib—Fluid retention—Liotrix—hypothyroidism	0.00262	0.0153	CcSEcCtD
Ponatinib—FGFR4—female gonad—hypothyroidism	0.0026	0.0107	CbGeAlD
Ponatinib—FGFR3—heart—hypothyroidism	0.00255	0.0105	CbGeAlD
Ponatinib—Dehydration—Levothyroxine—hypothyroidism	0.00253	0.0148	CcSEcCtD
Ponatinib—Dehydration—Dextrothyroxine—hypothyroidism	0.00253	0.0148	CcSEcCtD
Ponatinib—Sepsis—Liotrix—hypothyroidism	0.00239	0.014	CcSEcCtD
Ponatinib—FGFR4—testis—hypothyroidism	0.00231	0.00947	CbGeAlD
Ponatinib—Angina pectoris—Dextrothyroxine—hypothyroidism	0.00229	0.0134	CcSEcCtD
Ponatinib—Angina pectoris—Levothyroxine—hypothyroidism	0.00229	0.0134	CcSEcCtD
Ponatinib—BCR—adrenal cortex—hypothyroidism	0.00228	0.00937	CbGeAlD
Ponatinib—BCR—heart—hypothyroidism	0.00221	0.00906	CbGeAlD
Ponatinib—Cardiac failure congestive—Liotrix—hypothyroidism	0.00221	0.0129	CcSEcCtD
Ponatinib—FLT3—heart—hypothyroidism	0.00219	0.00899	CbGeAlD
Ponatinib—FGFR3—gonad—hypothyroidism	0.00219	0.00896	CbGeAlD
Ponatinib—FGFR4—liver—hypothyroidism	0.00218	0.00895	CbGeAlD
Ponatinib—Body temperature increased—Liothyronine—hypothyroidism	0.00215	0.0126	CcSEcCtD
Ponatinib—FGFR4—cerebellum—hypothyroidism	0.00213	0.00874	CbGeAlD
Ponatinib—Weight decreased—Dextrothyroxine—hypothyroidism	0.00213	0.0124	CcSEcCtD
Ponatinib—Weight decreased—Levothyroxine—hypothyroidism	0.00213	0.0124	CcSEcCtD
Ponatinib—FLT3—cardiovascular system—hypothyroidism	0.00207	0.00849	CbGeAlD
Ponatinib—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00207	0.0121	CcSEcCtD
Ponatinib—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00207	0.0121	CcSEcCtD
Ponatinib—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00206	0.012	CcSEcCtD
Ponatinib—Myocardial infarction—Levothyroxine—hypothyroidism	0.00206	0.012	CcSEcCtD
Ponatinib—Cardiac failure—Liotrix—hypothyroidism	0.00205	0.012	CcSEcCtD
Ponatinib—Cerebrovascular accident—Liotrix—hypothyroidism	0.00204	0.0119	CcSEcCtD
Ponatinib—FGFR1—heart—hypothyroidism	0.00197	0.00806	CbGeAlD
Ponatinib—LYN—blood—hypothyroidism	0.00191	0.00785	CbGeAlD
Ponatinib—FGFR3—adrenal gland—hypothyroidism	0.00191	0.00781	CbGeAlD
Ponatinib—BCR—gonad—hypothyroidism	0.00189	0.00776	CbGeAlD
Ponatinib—FLT3—gonad—hypothyroidism	0.00188	0.0077	CbGeAlD
Ponatinib—Blood creatinine increased—Liotrix—hypothyroidism	0.00188	0.0109	CcSEcCtD
Ponatinib—Dehydration—Liotrix—hypothyroidism	0.00186	0.0109	CcSEcCtD
Ponatinib—BCR—pituitary gland—hypothyroidism	0.00185	0.00757	CbGeAlD
Ponatinib—Hypokalaemia—Liotrix—hypothyroidism	0.00182	0.0106	CcSEcCtD
Ponatinib—RET—heart—hypothyroidism	0.00176	0.00721	CbGeAlD
Ponatinib—LCK—heart—hypothyroidism	0.00176	0.00721	CbGeAlD
Ponatinib—Flushing—Levothyroxine—hypothyroidism	0.00175	0.0102	CcSEcCtD
Ponatinib—Flushing—Dextrothyroxine—hypothyroidism	0.00175	0.0102	CcSEcCtD
Ponatinib—Abdominal distension—Liotrix—hypothyroidism	0.00174	0.0102	CcSEcCtD
Ponatinib—CYP3A4—urine—hypothyroidism	0.00173	0.0071	CbGeAlD
Ponatinib—CYP2D6—urine—hypothyroidism	0.0017	0.00699	CbGeAlD
Ponatinib—Angina pectoris—Liotrix—hypothyroidism	0.00169	0.00983	CcSEcCtD
Ponatinib—Arrhythmia—Levothyroxine—hypothyroidism	0.00168	0.00981	CcSEcCtD
Ponatinib—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00168	0.00981	CcSEcCtD
Ponatinib—Alopecia—Levothyroxine—hypothyroidism	0.00166	0.00971	CcSEcCtD
Ponatinib—Alopecia—Dextrothyroxine—hypothyroidism	0.00166	0.00971	CcSEcCtD
Ponatinib—TEK—adrenal cortex—hypothyroidism	0.00166	0.00679	CbGeAlD
Ponatinib—BCR—adrenal gland—hypothyroidism	0.00165	0.00676	CbGeAlD
Ponatinib—BCR—blood—hypothyroidism	0.00165	0.00676	CbGeAlD
Ponatinib—FGFR1—pituitary gland—hypothyroidism	0.00164	0.00673	CbGeAlD
Ponatinib—FLT3—adrenal gland—hypothyroidism	0.00164	0.00671	CbGeAlD
Ponatinib—FLT3—blood—hypothyroidism	0.00164	0.00671	CbGeAlD
Ponatinib—TEK—heart—hypothyroidism	0.0016	0.00657	CbGeAlD
Ponatinib—BCR—thyroid gland—hypothyroidism	0.00159	0.00652	CbGeAlD
Ponatinib—FGFR2—cardiovascular system—hypothyroidism	0.00158	0.00647	CbGeAlD
Ponatinib—FGFR3—testis—hypothyroidism	0.00158	0.00646	CbGeAlD
Ponatinib—Weight decreased—Liotrix—hypothyroidism	0.00157	0.00913	CcSEcCtD
Ponatinib—BCR—female gonad—hypothyroidism	0.00154	0.0063	CbGeAlD
Ponatinib—FLT3—female gonad—hypothyroidism	0.00153	0.00626	CbGeAlD
Ponatinib—Acute coronary syndrome—Liotrix—hypothyroidism	0.00152	0.00887	CcSEcCtD
Ponatinib—Myocardial infarction—Liotrix—hypothyroidism	0.00151	0.00882	CcSEcCtD
Ponatinib—TEK—cardiovascular system—hypothyroidism	0.00151	0.0062	CbGeAlD
Ponatinib—LYN—liver—hypothyroidism	0.0015	0.00614	CbGeAlD
Ponatinib—FGFR3—liver—hypothyroidism	0.00149	0.00611	CbGeAlD
Ponatinib—RET—pituitary gland—hypothyroidism	0.00147	0.00603	CbGeAlD
Ponatinib—FGFR1—adrenal gland—hypothyroidism	0.00147	0.00601	CbGeAlD
Ponatinib—FGFR3—cerebellum—hypothyroidism	0.00146	0.00597	CbGeAlD
Ponatinib—PDGFRA—heart—hypothyroidism	0.00145	0.00595	CbGeAlD
Ponatinib—SRC—heart—hypothyroidism	0.00142	0.00584	CbGeAlD
Ponatinib—FGFR1—thyroid gland—hypothyroidism	0.00142	0.0058	CbGeAlD
Ponatinib—Arthralgia—Dextrothyroxine—hypothyroidism	0.0014	0.00814	CcSEcCtD
Ponatinib—Arthralgia—Levothyroxine—hypothyroidism	0.0014	0.00814	CcSEcCtD
Ponatinib—Hypoaesthesia—Liotrix—hypothyroidism	0.00138	0.00804	CcSEcCtD
Ponatinib—PDGFRA—cardiovascular system—hypothyroidism	0.00137	0.00562	CbGeAlD
Ponatinib—FGFR1—female gonad—hypothyroidism	0.00137	0.00561	CbGeAlD
Ponatinib—BCR—testis—hypothyroidism	0.00136	0.00559	CbGeAlD
Ponatinib—KDR—adrenal cortex—hypothyroidism	0.00135	0.00555	CbGeAlD
Ponatinib—FLT3—testis—hypothyroidism	0.00135	0.00555	CbGeAlD
Ponatinib—SRC—cardiovascular system—hypothyroidism	0.00134	0.00551	CbGeAlD
Ponatinib—TEK—pituitary gland—hypothyroidism	0.00134	0.00549	CbGeAlD
Ponatinib—LCK—adrenal gland—hypothyroidism	0.00131	0.00538	CbGeAlD
Ponatinib—RET—adrenal gland—hypothyroidism	0.00131	0.00538	CbGeAlD
Ponatinib—RET—blood—hypothyroidism	0.00131	0.00538	CbGeAlD
Ponatinib—LCK—blood—hypothyroidism	0.00131	0.00538	CbGeAlD
Ponatinib—KDR—heart—hypothyroidism	0.00131	0.00537	CbGeAlD
Ponatinib—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00129	0.00755	CcSEcCtD
Ponatinib—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00129	0.00755	CcSEcCtD
Ponatinib—BCR—liver—hypothyroidism	0.00129	0.00529	CbGeAlD
Ponatinib—Flushing—Liotrix—hypothyroidism	0.00129	0.0075	CcSEcCtD
Ponatinib—FLT3—liver—hypothyroidism	0.00128	0.00525	CbGeAlD
Ponatinib—RET—thyroid gland—hypothyroidism	0.00127	0.00519	CbGeAlD
Ponatinib—LCK—thyroid gland—hypothyroidism	0.00127	0.00519	CbGeAlD
Ponatinib—BCR—cerebellum—hypothyroidism	0.00126	0.00516	CbGeAlD
Ponatinib—FLT3—cerebellum—hypothyroidism	0.00125	0.00513	CbGeAlD
Ponatinib—FGFR2—adrenal gland—hypothyroidism	0.00125	0.00511	CbGeAlD
Ponatinib—FGFR2—blood—hypothyroidism	0.00125	0.00511	CbGeAlD
Ponatinib—PDGFRA—gonad—hypothyroidism	0.00124	0.0051	CbGeAlD
Ponatinib—Arrhythmia—Liotrix—hypothyroidism	0.00124	0.00722	CcSEcCtD
Ponatinib—KDR—cardiovascular system—hypothyroidism	0.00124	0.00507	CbGeAlD
Ponatinib—LCK—female gonad—hypothyroidism	0.00122	0.00502	CbGeAlD
Ponatinib—Alopecia—Liotrix—hypothyroidism	0.00122	0.00714	CcSEcCtD
Ponatinib—SRC—gonad—hypothyroidism	0.00122	0.005	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00122	0.00711	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00122	0.00711	CcSEcCtD
Ponatinib—FGFR1—testis—hypothyroidism	0.00121	0.00497	CbGeAlD
Ponatinib—Insomnia—Dextrothyroxine—hypothyroidism	0.00121	0.00706	CcSEcCtD
Ponatinib—Insomnia—Levothyroxine—hypothyroidism	0.00121	0.00706	CcSEcCtD
Ponatinib—FGFR2—thyroid gland—hypothyroidism	0.0012	0.00494	CbGeAlD
Ponatinib—TEK—adrenal gland—hypothyroidism	0.0012	0.0049	CbGeAlD
Ponatinib—TEK—blood—hypothyroidism	0.0012	0.0049	CbGeAlD
Ponatinib—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00119	0.00696	CcSEcCtD
Ponatinib—Dyspnoea—Levothyroxine—hypothyroidism	0.00119	0.00696	CcSEcCtD
Ponatinib—FGFR2—female gonad—hypothyroidism	0.00116	0.00477	CbGeAlD
Ponatinib—KIT—heart—hypothyroidism	0.00116	0.00476	CbGeAlD
Ponatinib—TEK—thyroid gland—hypothyroidism	0.00115	0.00473	CbGeAlD
Ponatinib—Fatigue—Levothyroxine—hypothyroidism	0.00115	0.00673	CcSEcCtD
Ponatinib—Fatigue—Dextrothyroxine—hypothyroidism	0.00115	0.00673	CcSEcCtD
Ponatinib—FGFR1—liver—hypothyroidism	0.00115	0.0047	CbGeAlD
Ponatinib—Vision blurred—Liotrix—hypothyroidism	0.00114	0.00663	CcSEcCtD
Ponatinib—FGFR1—cerebellum—hypothyroidism	0.00112	0.00459	CbGeAlD
Ponatinib—TEK—female gonad—hypothyroidism	0.00111	0.00457	CbGeAlD
Ponatinib—KIT—cardiovascular system—hypothyroidism	0.00109	0.00449	CbGeAlD
Ponatinib—KDR—pituitary gland—hypothyroidism	0.00109	0.00449	CbGeAlD
Ponatinib—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00109	0.00638	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00109	0.00638	CcSEcCtD
Ponatinib—LCK—testis—hypothyroidism	0.00109	0.00445	CbGeAlD
Ponatinib—RET—testis—hypothyroidism	0.00109	0.00445	CbGeAlD
Ponatinib—PDGFRA—adrenal gland—hypothyroidism	0.00108	0.00444	CbGeAlD
Ponatinib—PDGFRA—blood—hypothyroidism	0.00108	0.00444	CbGeAlD
Ponatinib—SRC—adrenal gland—hypothyroidism	0.00106	0.00436	CbGeAlD
Ponatinib—SRC—blood—hypothyroidism	0.00106	0.00436	CbGeAlD
Ponatinib—ABCB11—testis—hypothyroidism	0.00106	0.00435	CbGeAlD
Ponatinib—Body temperature increased—Levothyroxine—hypothyroidism	0.00106	0.00617	CcSEcCtD
Ponatinib—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00106	0.00617	CcSEcCtD
Ponatinib—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00106	0.00617	CcSEcCtD
Ponatinib—Abdominal pain—Levothyroxine—hypothyroidism	0.00106	0.00617	CcSEcCtD
Ponatinib—PDGFRA—thyroid gland—hypothyroidism	0.00105	0.00429	CbGeAlD
Ponatinib—ABL1—adrenal cortex—hypothyroidism	0.00104	0.00428	CbGeAlD
Ponatinib—Hypertension—Liotrix—hypothyroidism	0.00104	0.00607	CcSEcCtD
Ponatinib—FGFR2—testis—hypothyroidism	0.00103	0.00423	CbGeAlD
Ponatinib—Arthralgia—Liotrix—hypothyroidism	0.00103	0.00599	CcSEcCtD
Ponatinib—LCK—liver—hypothyroidism	0.00103	0.00421	CbGeAlD
Ponatinib—SRC—thyroid gland—hypothyroidism	0.00103	0.0042	CbGeAlD
Ponatinib—PDGFRA—female gonad—hypothyroidism	0.00101	0.00414	CbGeAlD
Ponatinib—ABL1—heart—hypothyroidism	0.00101	0.00414	CbGeAlD
Ponatinib—RET—cerebellum—hypothyroidism	0.001	0.00411	CbGeAlD
Ponatinib—ABCB11—liver—hypothyroidism	0.001	0.00411	CbGeAlD
Ponatinib—KIT—gonad—hypothyroidism	0.000994	0.00407	CbGeAlD
Ponatinib—SRC—female gonad—hypothyroidism	0.000991	0.00406	CbGeAlD
Ponatinib—TEK—testis—hypothyroidism	0.000989	0.00405	CbGeAlD
Ponatinib—Oedema—Liotrix—hypothyroidism	0.000984	0.00574	CcSEcCtD
Ponatinib—Infection—Liotrix—hypothyroidism	0.000977	0.0057	CcSEcCtD
Ponatinib—KDR—adrenal gland—hypothyroidism	0.000977	0.00401	CbGeAlD
Ponatinib—KDR—blood—hypothyroidism	0.000977	0.00401	CbGeAlD
Ponatinib—FGFR2—liver—hypothyroidism	0.000975	0.004	CbGeAlD
Ponatinib—KIT—pituitary gland—hypothyroidism	0.000969	0.00398	CbGeAlD
Ponatinib—Asthenia—Levothyroxine—hypothyroidism	0.00096	0.0056	CcSEcCtD
Ponatinib—Asthenia—Dextrothyroxine—hypothyroidism	0.00096	0.0056	CcSEcCtD
Ponatinib—ABL1—cardiovascular system—hypothyroidism	0.000953	0.00391	CbGeAlD
Ponatinib—FGFR2—cerebellum—hypothyroidism	0.000953	0.00391	CbGeAlD
Ponatinib—Hyperhidrosis—Liotrix—hypothyroidism	0.000951	0.00555	CcSEcCtD
Ponatinib—Pruritus—Levothyroxine—hypothyroidism	0.000946	0.00552	CcSEcCtD
Ponatinib—Pruritus—Dextrothyroxine—hypothyroidism	0.000946	0.00552	CcSEcCtD
Ponatinib—KDR—thyroid gland—hypothyroidism	0.000943	0.00387	CbGeAlD
Ponatinib—TEK—liver—hypothyroidism	0.000935	0.00383	CbGeAlD
Ponatinib—Diarrhoea—Levothyroxine—hypothyroidism	0.000915	0.00534	CcSEcCtD
Ponatinib—Diarrhoea—Dextrothyroxine—hypothyroidism	0.000915	0.00534	CcSEcCtD
Ponatinib—TEK—cerebellum—hypothyroidism	0.000913	0.00374	CbGeAlD
Ponatinib—KDR—female gonad—hypothyroidism	0.000911	0.00374	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.000896	0.00523	CcSEcCtD
Ponatinib—PDGFRA—testis—hypothyroidism	0.000896	0.00367	CbGeAlD
Ponatinib—Insomnia—Liotrix—hypothyroidism	0.00089	0.00519	CcSEcCtD
Ponatinib—Paraesthesia—Liotrix—hypothyroidism	0.000884	0.00516	CcSEcCtD
Ponatinib—SRC—testis—hypothyroidism	0.000879	0.0036	CbGeAlD
Ponatinib—Dyspnoea—Liotrix—hypothyroidism	0.000877	0.00512	CcSEcCtD
Ponatinib—KIT—adrenal gland—hypothyroidism	0.000866	0.00355	CbGeAlD
Ponatinib—KIT—blood—hypothyroidism	0.000866	0.00355	CbGeAlD
Ponatinib—ABL1—gonad—hypothyroidism	0.000865	0.00355	CbGeAlD
Ponatinib—Decreased appetite—Liotrix—hypothyroidism	0.000855	0.00499	CcSEcCtD
Ponatinib—Vomiting—Levothyroxine—hypothyroidism	0.00085	0.00496	CcSEcCtD
Ponatinib—Vomiting—Dextrothyroxine—hypothyroidism	0.00085	0.00496	CcSEcCtD
Ponatinib—Fatigue—Liotrix—hypothyroidism	0.000848	0.00495	CcSEcCtD
Ponatinib—PDGFRA—liver—hypothyroidism	0.000847	0.00347	CbGeAlD
Ponatinib—ABL1—pituitary gland—hypothyroidism	0.000844	0.00346	CbGeAlD
Ponatinib—Rash—Levothyroxine—hypothyroidism	0.000843	0.00492	CcSEcCtD
Ponatinib—Rash—Dextrothyroxine—hypothyroidism	0.000843	0.00492	CcSEcCtD
Ponatinib—Dermatitis—Levothyroxine—hypothyroidism	0.000843	0.00492	CcSEcCtD
Ponatinib—Dermatitis—Dextrothyroxine—hypothyroidism	0.000843	0.00492	CcSEcCtD
Ponatinib—Constipation—Liotrix—hypothyroidism	0.000841	0.00491	CcSEcCtD
Ponatinib—Headache—Levothyroxine—hypothyroidism	0.000838	0.00489	CcSEcCtD
Ponatinib—Headache—Dextrothyroxine—hypothyroidism	0.000838	0.00489	CcSEcCtD
Ponatinib—KIT—thyroid gland—hypothyroidism	0.000836	0.00343	CbGeAlD
Ponatinib—SRC—liver—hypothyroidism	0.000831	0.00341	CbGeAlD
Ponatinib—PDGFRA—cerebellum—hypothyroidism	0.000827	0.00339	CbGeAlD
Ponatinib—SRC—cerebellum—hypothyroidism	0.000811	0.00333	CbGeAlD
Ponatinib—KDR—testis—hypothyroidism	0.000808	0.00331	CbGeAlD
Ponatinib—KIT—female gonad—hypothyroidism	0.000808	0.00331	CbGeAlD
Ponatinib—Gastrointestinal pain—Liotrix—hypothyroidism	0.000805	0.00469	CcSEcCtD
Ponatinib—Nausea—Dextrothyroxine—hypothyroidism	0.000795	0.00464	CcSEcCtD
Ponatinib—Nausea—Levothyroxine—hypothyroidism	0.000795	0.00464	CcSEcCtD
Ponatinib—Body temperature increased—Liotrix—hypothyroidism	0.000778	0.00454	CcSEcCtD
Ponatinib—Abdominal pain—Liotrix—hypothyroidism	0.000778	0.00454	CcSEcCtD
Ponatinib—KDR—liver—hypothyroidism	0.000764	0.00313	CbGeAlD
Ponatinib—ABL1—adrenal gland—hypothyroidism	0.000754	0.00309	CbGeAlD
Ponatinib—ABL1—blood—hypothyroidism	0.000754	0.00309	CbGeAlD
Ponatinib—KDR—cerebellum—hypothyroidism	0.000746	0.00306	CbGeAlD
Ponatinib—ABL1—thyroid gland—hypothyroidism	0.000727	0.00298	CbGeAlD
Ponatinib—KIT—testis—hypothyroidism	0.000716	0.00294	CbGeAlD
Ponatinib—Asthenia—Liotrix—hypothyroidism	0.000706	0.00412	CcSEcCtD
Ponatinib—ABL1—female gonad—hypothyroidism	0.000703	0.00288	CbGeAlD
Ponatinib—Pruritus—Liotrix—hypothyroidism	0.000696	0.00406	CcSEcCtD
Ponatinib—KIT—liver—hypothyroidism	0.000677	0.00278	CbGeAlD
Ponatinib—Diarrhoea—Liotrix—hypothyroidism	0.000673	0.00393	CcSEcCtD
Ponatinib—KIT—cerebellum—hypothyroidism	0.000661	0.00271	CbGeAlD
Ponatinib—ABCG2—adrenal cortex—hypothyroidism	0.000659	0.0027	CbGeAlD
Ponatinib—Dizziness—Liotrix—hypothyroidism	0.000651	0.0038	CcSEcCtD
Ponatinib—ABCG2—heart—hypothyroidism	0.000637	0.00261	CbGeAlD
Ponatinib—Vomiting—Liotrix—hypothyroidism	0.000626	0.00365	CcSEcCtD
Ponatinib—ABL1—testis—hypothyroidism	0.000623	0.00256	CbGeAlD
Ponatinib—Rash—Liotrix—hypothyroidism	0.00062	0.00362	CcSEcCtD
Ponatinib—Dermatitis—Liotrix—hypothyroidism	0.00062	0.00362	CcSEcCtD
Ponatinib—Headache—Liotrix—hypothyroidism	0.000616	0.0036	CcSEcCtD
Ponatinib—ABL1—liver—hypothyroidism	0.000589	0.00242	CbGeAlD
Ponatinib—Nausea—Liotrix—hypothyroidism	0.000584	0.00341	CcSEcCtD
Ponatinib—ABL1—cerebellum—hypothyroidism	0.000576	0.00236	CbGeAlD
Ponatinib—CYP2C8—pituitary gland—hypothyroidism	0.000547	0.00224	CbGeAlD
Ponatinib—ABCG2—pituitary gland—hypothyroidism	0.000532	0.00218	CbGeAlD
Ponatinib—CYP2C8—blood—hypothyroidism	0.000489	0.002	CbGeAlD
Ponatinib—ABCG2—adrenal gland—hypothyroidism	0.000475	0.00195	CbGeAlD
Ponatinib—ABCG2—blood—hypothyroidism	0.000475	0.00195	CbGeAlD
Ponatinib—ABCG2—thyroid gland—hypothyroidism	0.000459	0.00188	CbGeAlD
Ponatinib—ABCG2—female gonad—hypothyroidism	0.000443	0.00182	CbGeAlD
Ponatinib—CYP3A5—blood—hypothyroidism	0.000441	0.00181	CbGeAlD
Ponatinib—CYP3A5—female gonad—hypothyroidism	0.000411	0.00169	CbGeAlD
Ponatinib—CYP2C8—testis—hypothyroidism	0.000404	0.00166	CbGeAlD
Ponatinib—ABCG2—testis—hypothyroidism	0.000393	0.00161	CbGeAlD
Ponatinib—CYP2C8—liver—hypothyroidism	0.000382	0.00157	CbGeAlD
Ponatinib—ABCG2—liver—hypothyroidism	0.000372	0.00152	CbGeAlD
Ponatinib—ABCG2—cerebellum—hypothyroidism	0.000363	0.00149	CbGeAlD
Ponatinib—CYP3A5—liver—hypothyroidism	0.000345	0.00141	CbGeAlD
Ponatinib—CYP3A4—blood—hypothyroidism	0.000331	0.00136	CbGeAlD
Ponatinib—CYP2D6—blood—hypothyroidism	0.000326	0.00134	CbGeAlD
Ponatinib—ABCB1—adrenal cortex—hypothyroidism	0.000325	0.00133	CbGeAlD
Ponatinib—ABCB1—heart—hypothyroidism	0.000314	0.00129	CbGeAlD
Ponatinib—CYP2D6—female gonad—hypothyroidism	0.000304	0.00125	CbGeAlD
Ponatinib—ABCB1—cardiovascular system—hypothyroidism	0.000296	0.00122	CbGeAlD
Ponatinib—CYP2D6—testis—hypothyroidism	0.00027	0.00111	CbGeAlD
Ponatinib—ABCB1—gonad—hypothyroidism	0.000269	0.0011	CbGeAlD
Ponatinib—ABCB1—pituitary gland—hypothyroidism	0.000262	0.00108	CbGeAlD
Ponatinib—CYP3A4—liver—hypothyroidism	0.000259	0.00106	CbGeAlD
Ponatinib—CYP2D6—liver—hypothyroidism	0.000255	0.00104	CbGeAlD
Ponatinib—CYP2D6—cerebellum—hypothyroidism	0.000249	0.00102	CbGeAlD
Ponatinib—ABCB1—adrenal gland—hypothyroidism	0.000234	0.000961	CbGeAlD
Ponatinib—ABCB1—blood—hypothyroidism	0.000234	0.000961	CbGeAlD
Ponatinib—ABCB1—thyroid gland—hypothyroidism	0.000226	0.000928	CbGeAlD
Ponatinib—ABCB1—female gonad—hypothyroidism	0.000219	0.000896	CbGeAlD
Ponatinib—ABCB1—testis—hypothyroidism	0.000194	0.000795	CbGeAlD
Ponatinib—ABCB1—liver—hypothyroidism	0.000183	0.000752	CbGeAlD
Ponatinib—ABCB1—cerebellum—hypothyroidism	0.000179	0.000734	CbGeAlD
Ponatinib—KDR—Developmental Biology—VAV3—hypothyroidism	0.00015	0.00107	CbGpPWpGaD
Ponatinib—SRC—Senescence and Autophagy in Cancer—IGF1—hypothyroidism	0.000149	0.00107	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—CLTC—hypothyroidism	0.000149	0.00106	CbGpPWpGaD
Ponatinib—PDGFRA—Focal Adhesion—IGF1—hypothyroidism	0.000145	0.00104	CbGpPWpGaD
Ponatinib—FGFR1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000145	0.00103	CbGpPWpGaD
Ponatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000145	0.00103	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CLTC—hypothyroidism	0.000143	0.00102	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TRH—hypothyroidism	0.000142	0.00101	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—SH2B3—hypothyroidism	0.000138	0.000987	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—SH2B3—hypothyroidism	0.000138	0.000982	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—VAV3—hypothyroidism	0.000136	0.000968	CbGpPWpGaD
Ponatinib—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000135	0.000966	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—PRL—hypothyroidism	0.000135	0.000964	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—IYD—hypothyroidism	0.000135	0.000963	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—VAV3—hypothyroidism	0.000135	0.000963	CbGpPWpGaD
Ponatinib—CYP2C8—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000134	0.000954	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.000134	0.000954	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—PRL—hypothyroidism	0.000129	0.00092	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CLTC—hypothyroidism	0.000129	0.000919	CbGpPWpGaD
Ponatinib—ABL1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000127	0.000905	CbGpPWpGaD
Ponatinib—KIT—Immune System—CLTC—hypothyroidism	0.000127	0.000903	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CLTC—hypothyroidism	0.000126	0.000902	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TSHB—hypothyroidism	0.000126	0.0009	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TSHR—hypothyroidism	0.000126	0.0009	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—VAV3—hypothyroidism	0.000123	0.000876	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CLTC—hypothyroidism	0.000121	0.000864	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CLTC—hypothyroidism	0.00012	0.000857	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CLTC—hypothyroidism	0.00012	0.000855	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—VAV3—hypothyroidism	0.000119	0.000851	CbGpPWpGaD
Ponatinib—FGFR4—Disease—PRL—hypothyroidism	0.000119	0.00085	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—PRL—hypothyroidism	0.000118	0.000845	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ATP5O—hypothyroidism	0.000115	0.000819	CbGpPWpGaD
Ponatinib—LYN—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	0.000113	0.000809	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—SH2B3—hypothyroidism	0.000113	0.000809	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—SH2B3—hypothyroidism	0.000112	0.000802	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—VAV3—hypothyroidism	0.00011	0.000785	CbGpPWpGaD
Ponatinib—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00011	0.000783	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—VAV3—hypothyroidism	0.00011	0.000781	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—VAV3—hypothyroidism	0.000109	0.000776	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000108	0.000771	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—TPO—hypothyroidism	0.000108	0.00077	CbGpPWpGaD
Ponatinib—LYN—Immune System—CLTC—hypothyroidism	0.000106	0.000754	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CLTC—hypothyroidism	0.000106	0.000753	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—AVP—hypothyroidism	0.000106	0.000753	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CLTC—hypothyroidism	0.000105	0.00075	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TRH—hypothyroidism	0.000105	0.000747	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—VAV3—hypothyroidism	0.000104	0.000744	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—VAV3—hypothyroidism	0.000102	0.00073	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—SH2B3—hypothyroidism	0.0001	0.000716	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—VAV3—hypothyroidism	9.85e-05	0.000702	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—VAV3—hypothyroidism	9.72e-05	0.000693	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—VAV3—hypothyroidism	9.69e-05	0.000691	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—VAV3—hypothyroidism	9.68e-05	0.000691	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—IYD—hypothyroidism	9.68e-05	0.00069	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—VAV3—hypothyroidism	9.64e-05	0.000687	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—PRL—hypothyroidism	9.55e-05	0.000681	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—VAV3—hypothyroidism	9.5e-05	0.000677	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—VAV3—hypothyroidism	9.45e-05	0.000674	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TSHB—hypothyroidism	9.33e-05	0.000666	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TSHR—hypothyroidism	9.33e-05	0.000666	CbGpPWpGaD
Ponatinib—LCK—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	9.3e-05	0.000663	CbGpPWpGaD
Ponatinib—SRC—Focal Adhesion—IGF1—hypothyroidism	9.29e-05	0.000663	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	9.25e-05	0.00066	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TRH—hypothyroidism	9.12e-05	0.000651	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	8.95e-05	0.000639	CbGpPWpGaD
Ponatinib—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	8.86e-05	0.000632	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—VAV3—hypothyroidism	8.83e-05	0.00063	CbGpPWpGaD
Ponatinib—FGFR3—Disease—PRL—hypothyroidism	8.81e-05	0.000629	CbGpPWpGaD
Ponatinib—LCK—Immune System—CLTC—hypothyroidism	8.66e-05	0.000618	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—VAV3—hypothyroidism	8.55e-05	0.00061	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—VAV3—hypothyroidism	8.51e-05	0.000607	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—IYD—hypothyroidism	8.38e-05	0.000598	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—PRL—hypothyroidism	8.34e-05	0.000595	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CLTC—hypothyroidism	8.33e-05	0.000594	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—SH2B3—hypothyroidism	8.32e-05	0.000593	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	8.23e-05	0.000587	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ATP5O—hypothyroidism	8.23e-05	0.000587	CbGpPWpGaD
Ponatinib—CYP3A5—Biological oxidations—POMC—hypothyroidism	8.2e-05	0.000585	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CLTC—hypothyroidism	8.18e-05	0.000584	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TSHR—hypothyroidism	8.13e-05	0.00058	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TSHB—hypothyroidism	8.13e-05	0.00058	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	7.99e-05	0.00057	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—VAV3—hypothyroidism	7.79e-05	0.000555	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CLTC—hypothyroidism	7.77e-05	0.000554	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CLTC—hypothyroidism	7.75e-05	0.000553	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TPO—hypothyroidism	7.74e-05	0.000552	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—VAV3—hypothyroidism	7.72e-05	0.00055	CbGpPWpGaD
Ponatinib—SRC—Immune System—CLTC—hypothyroidism	7.67e-05	0.000547	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—TSHB—hypothyroidism	7.56e-05	0.000539	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AVP—hypothyroidism	7.44e-05	0.00053	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—IYD—hypothyroidism	7.3e-05	0.000521	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—SH2B3—hypothyroidism	7.25e-05	0.000517	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TRH—hypothyroidism	7.2e-05	0.000514	CbGpPWpGaD
Ponatinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	7.18e-05	0.000512	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ATP5O—hypothyroidism	7.13e-05	0.000508	CbGpPWpGaD
Ponatinib—CYP2C8—Biological oxidations—POMC—hypothyroidism	7.1e-05	0.000507	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TRH—hypothyroidism	7.07e-05	0.000504	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—VAV3—hypothyroidism	7.03e-05	0.000501	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—POMC—hypothyroidism	7.01e-05	0.0005	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—VAV3—hypothyroidism	7.01e-05	0.0005	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—VAV3—hypothyroidism	6.89e-05	0.000492	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—IYD—hypothyroidism	6.88e-05	0.000491	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CLTC—hypothyroidism	6.83e-05	0.000487	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IGF1—hypothyroidism	6.75e-05	0.000481	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3C2A—hypothyroidism	6.74e-05	0.000481	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TRH—hypothyroidism	6.71e-05	0.000479	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TPO—hypothyroidism	6.7e-05	0.000478	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TRH—hypothyroidism	6.7e-05	0.000478	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	6.65e-05	0.000474	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—PRL—hypothyroidism	6.57e-05	0.000468	CbGpPWpGaD
Ponatinib—KIT—Immune System—PRL—hypothyroidism	6.45e-05	0.00046	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TSHB—hypothyroidism	6.42e-05	0.000458	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TSHR—hypothyroidism	6.42e-05	0.000458	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TSHB—hypothyroidism	6.3e-05	0.00045	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TSHR—hypothyroidism	6.3e-05	0.00045	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—AVP—hypothyroidism	6.29e-05	0.000449	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ATP5O—hypothyroidism	6.21e-05	0.000443	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	6.21e-05	0.000443	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—VAV3—hypothyroidism	6.21e-05	0.000443	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PRL—hypothyroidism	6.17e-05	0.00044	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PRL—hypothyroidism	6.12e-05	0.000436	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PRL—hypothyroidism	6.1e-05	0.000435	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—VAV3—hypothyroidism	6.07e-05	0.000433	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PRL—hypothyroidism	6.06e-05	0.000432	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TSHB—hypothyroidism	5.98e-05	0.000427	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TSHR—hypothyroidism	5.98e-05	0.000427	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TSHB—hypothyroidism	5.97e-05	0.000426	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TSHR—hypothyroidism	5.97e-05	0.000426	CbGpPWpGaD
Ponatinib—KIT—Immune System—VAV3—hypothyroidism	5.97e-05	0.000425	CbGpPWpGaD
Ponatinib—KIT—Disease—PRL—hypothyroidism	5.95e-05	0.000425	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TRH—hypothyroidism	5.91e-05	0.000421	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ATP5O—hypothyroidism	5.85e-05	0.000417	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—IGF1—hypothyroidism	5.85e-05	0.000417	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TPO—hypothyroidism	5.84e-05	0.000416	CbGpPWpGaD
Ponatinib—CYP2D6—Biological oxidations—POMC—hypothyroidism	5.83e-05	0.000416	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—IGF1—hypothyroidism	5.82e-05	0.000415	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SH2B3—hypothyroidism	5.72e-05	0.000408	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VAV3—hypothyroidism	5.71e-05	0.000407	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—VAV3—hypothyroidism	5.66e-05	0.000404	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—SLC5A5—hypothyroidism	5.66e-05	0.000404	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PRL—hypothyroidism	5.65e-05	0.000403	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—VAV3—hypothyroidism	5.65e-05	0.000403	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PRL—hypothyroidism	5.64e-05	0.000402	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SH2B3—hypothyroidism	5.62e-05	0.000401	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CLTC—hypothyroidism	5.6e-05	0.000399	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TPO—hypothyroidism	5.5e-05	0.000392	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AVP—hypothyroidism	5.5e-05	0.000392	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	5.48e-05	0.00039	CbGpPWpGaD
Ponatinib—LYN—Immune System—PRL—hypothyroidism	5.38e-05	0.000384	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PRL—hypothyroidism	5.38e-05	0.000383	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PRL—hypothyroidism	5.36e-05	0.000382	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SH2B3—hypothyroidism	5.33e-05	0.00038	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SH2B3—hypothyroidism	5.32e-05	0.000379	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TSHB—hypothyroidism	5.26e-05	0.000375	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TSHR—hypothyroidism	5.26e-05	0.000375	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—TSHB—hypothyroidism	5e-05	0.000357	CbGpPWpGaD
Ponatinib—LYN—Immune System—VAV3—hypothyroidism	4.98e-05	0.000355	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VAV3—hypothyroidism	4.97e-05	0.000355	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CLTC—hypothyroidism	4.96e-05	0.000354	CbGpPWpGaD
Ponatinib—ABL1—Immune System—VAV3—hypothyroidism	4.96e-05	0.000354	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—POMC—hypothyroidism	4.94e-05	0.000352	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TRH—hypothyroidism	4.84e-05	0.000345	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—IGF1—hypothyroidism	4.79e-05	0.000342	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AVP—hypothyroidism	4.79e-05	0.000342	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IGF1—hypothyroidism	4.75e-05	0.000339	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SH2B3—hypothyroidism	4.69e-05	0.000335	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—IYD—hypothyroidism	4.5e-05	0.000321	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3C2A—hypothyroidism	4.46e-05	0.000318	CbGpPWpGaD
Ponatinib—LCK—Immune System—PRL—hypothyroidism	4.41e-05	0.000315	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	4.32e-05	0.000308	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TSHB—hypothyroidism	4.31e-05	0.000308	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TSHR—hypothyroidism	4.31e-05	0.000308	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TRH—hypothyroidism	4.29e-05	0.000306	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PRL—hypothyroidism	4.24e-05	0.000303	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—IGF1—hypothyroidism	4.24e-05	0.000303	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PRL—hypothyroidism	4.17e-05	0.000297	CbGpPWpGaD
Ponatinib—LCK—Immune System—VAV3—hypothyroidism	4.08e-05	0.000291	CbGpPWpGaD
Ponatinib—LCK—Disease—PRL—hypothyroidism	4.07e-05	0.000291	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PRL—hypothyroidism	3.96e-05	0.000282	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PRL—hypothyroidism	3.95e-05	0.000281	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VAV3—hypothyroidism	3.93e-05	0.00028	CbGpPWpGaD
Ponatinib—SRC—Immune System—PRL—hypothyroidism	3.91e-05	0.000279	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VAV3—hypothyroidism	3.86e-05	0.000275	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SH2B3—hypothyroidism	3.85e-05	0.000274	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ATP5O—hypothyroidism	3.83e-05	0.000273	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TSHB—hypothyroidism	3.82e-05	0.000272	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TSHR—hypothyroidism	3.82e-05	0.000272	CbGpPWpGaD
Ponatinib—CYP3A4—Biological oxidations—POMC—hypothyroidism	3.81e-05	0.000272	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AVP—hypothyroidism	3.78e-05	0.00027	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—SLC5A5—hypothyroidism	3.74e-05	0.000267	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AVP—hypothyroidism	3.72e-05	0.000265	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VAV3—hypothyroidism	3.66e-05	0.000261	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—POMC—hypothyroidism	3.66e-05	0.000261	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VAV3—hypothyroidism	3.65e-05	0.00026	CbGpPWpGaD
Ponatinib—SRC—Immune System—VAV3—hypothyroidism	3.61e-05	0.000258	CbGpPWpGaD
Ponatinib—SRC—Disease—PRL—hypothyroidism	3.61e-05	0.000257	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TPO—hypothyroidism	3.6e-05	0.000257	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TSHB—hypothyroidism	3.58e-05	0.000255	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AVP—hypothyroidism	3.53e-05	0.000251	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AVP—hypothyroidism	3.52e-05	0.000251	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IGF1—hypothyroidism	3.52e-05	0.000251	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PRL—hypothyroidism	3.48e-05	0.000248	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SH2B3—hypothyroidism	3.4e-05	0.000243	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	3.4e-05	0.000243	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VAV3—hypothyroidism	3.22e-05	0.00023	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	3.19e-05	0.000228	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—POMC—hypothyroidism	3.18e-05	0.000227	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AVP—hypothyroidism	3.1e-05	0.000221	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TSHB—hypothyroidism	3.1e-05	0.000221	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IGF1—hypothyroidism	3.06e-05	0.000218	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—POMC—hypothyroidism	2.96e-05	0.000211	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PRL—hypothyroidism	2.85e-05	0.000203	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	2.76e-05	0.000197	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	2.73e-05	0.000195	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TSHB—hypothyroidism	2.7e-05	0.000193	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—SLC5A5—hypothyroidism	2.68e-05	0.000191	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VAV3—hypothyroidism	2.64e-05	0.000188	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TSHB—hypothyroidism	2.55e-05	0.000182	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AVP—hypothyroidism	2.54e-05	0.000181	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PRL—hypothyroidism	2.53e-05	0.00018	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—POMC—hypothyroidism	2.51e-05	0.000179	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—POMC—hypothyroidism	2.47e-05	0.000176	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IGF1—hypothyroidism	2.42e-05	0.000172	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3C2A—hypothyroidism	2.41e-05	0.000172	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IGF1—hypothyroidism	2.38e-05	0.000169	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—POMC—hypothyroidism	2.34e-05	0.000167	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—POMC—hypothyroidism	2.34e-05	0.000167	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VAV3—hypothyroidism	2.34e-05	0.000167	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC5A5—hypothyroidism	2.32e-05	0.000166	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	2.27e-05	0.000162	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IGF1—hypothyroidism	2.25e-05	0.000161	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AVP—hypothyroidism	2.25e-05	0.000161	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IGF1—hypothyroidism	2.25e-05	0.00016	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—POMC—hypothyroidism	2.06e-05	0.000147	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC5A5—hypothyroidism	2.02e-05	0.000144	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF1—hypothyroidism	1.98e-05	0.000141	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—POMC—hypothyroidism	1.96e-05	0.00014	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC5A5—hypothyroidism	1.91e-05	0.000136	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—POMC—hypothyroidism	1.69e-05	0.000121	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TSHB—hypothyroidism	1.67e-05	0.000119	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—hypothyroidism	1.63e-05	0.000116	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—hypothyroidism	1.5e-05	0.000107	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	1.48e-05	0.000106	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—hypothyroidism	1.44e-05	0.000103	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—hypothyroidism	1.4e-05	0.0001	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—hypothyroidism	1.25e-05	8.89e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—hypothyroidism	1.22e-05	8.67e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—hypothyroidism	1.06e-05	7.55e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—hypothyroidism	9.97e-06	7.11e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—hypothyroidism	6.52e-06	4.65e-05	CbGpPWpGaD
